Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Common Equity (2016 - 2025)

Amicus Therapeutics' Common Equity history spans 16 years, with the latest figure at $274.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 41.33% year-over-year to $274.2 million, compared with a TTM value of $274.2 million through Dec 2025, up 41.33%, and an annual FY2025 reading of $274.2 million, up 41.33% over the prior year.
  • Common Equity for Q4 2025 was $274.2 million at Amicus Therapeutics, up from $230.4 million in the prior quarter.
  • The five-year high for Common Equity was $376.6 million in Q3 2021, with the low at $102.6 million in Q1 2023.
  • Average Common Equity over 5 years is $193.1 million, with a median of $186.2 million recorded in 2024.
  • Year-over-year, Common Equity plummeted 64.8% in 2022 and then surged 54.16% in 2025.
  • Tracing FOLD's Common Equity over 5 years: stood at $307.4 million in 2021, then plummeted by 59.97% to $123.0 million in 2022, then surged by 30.17% to $160.2 million in 2023, then increased by 21.15% to $194.0 million in 2024, then soared by 41.33% to $274.2 million in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Common Equity are $274.2 million (Q4 2025), $230.4 million (Q3 2025), and $204.3 million (Q2 2025).